# US 2012/0251578 A1 · Diagnostic, Therapeutic And A Vaccine Against Treponemes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251578 A1
- Document ID: US20120251578A1
- Status: Published application
- Kind: A1
- Application number: 13/433,258
- Filed: 2012-03-28
- Published: 2012-10-04
- Earliest claimed: 2011-03-29
- Inventors: Hank (Henry) Michael Lefler
- Web page: https://patentgrep.com/patent/US20120251578A1

## CPC

- A61K 39/0225: {Spirochetes, e.g. Treponema, Leptospira, Borrelia}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- G01N 33/571: for venereal disease, e.g. syphilis, gonorrhoea {(herpes G01N33/56994; chlamydia G01N33/56927)}
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- G01N 2333/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The development of a diagnostic, therapeutic and making and administering a vaccine against ungulate diseases which involves spirochete bacteria in particular, Treponemes.

## Claims

### Claim 1

A vaccine for the immunization of ungulates against Treponemes, comprising an effective immunogenic amount of either HS activated or HS induced Treponema spirochetes, fragments, polypeptides, subunits or recombinates therefrom and/or vector expression therein, dispersed in a physiologically-acceptable, non-toxic liquid vehicle.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein the Treponemes are involved in PDD, CODD and/or ungulate gingivitis.

### Claim 3 (depends on 1)

The vaccine of claim 1, wherein the inactivated Treponema spirochetes fragments, distinct from a whole-cell Treponema spirochete, are obtained by culturing whole-cell spirochetes from a culture medium containing HS, distinct from the original biopsy or tissue sample, by centrifugation, selective cultures conditions and/or lyophilizing the separated spirochetes.

### Claim 4 (depends on 2)

The vaccine of claim 2, wherein the immunogenic Treponema spirochetes are originally derived from skin and/or blood from mammalian species infected with Treponema and subcultures include the addition of HS.

### Claim 5 (depends on 1)

A method for the immunization of an ungulate against PDD and CODD and/or gingivitis comprising administration of an effective amount of the vaccine in said ungulate of claim 1.

### Claim 6 (depends on 4)

The method of claim 4 wherein the vaccine is administered by injection.

### Claim 7 (depends on 5)

The method of claim 5 wherein a plurality of injections of the vaccine are administered.

### Claim 8 (depends on 4)

The method of claim 4 wherein the vaccine is combined with at least one of leptospiral bacteria and/or bovine, ovine and/or ungulate vaccines.

### Claim 9

A method for the use of the HS induced gene or genes and/or resultant protein as a diagnostic for Treponemal infection in ungulates.

### Claim 10

A method for the use of the HS induced gene or resultant protein as a therapeutic and/or combined with a pharmaceutical as a therapeutic for Treponemal infection in ungulates.
